Delving into the Latest Updates on HSK-29116 with Synapse

Overview

Basic Info

Drug Type

Proteolysis-targeting chimeras (PROTAC)

Synonyms

HSK-29116, HSK29116

Target

BTK

Action

inhibitors

Mechanism

BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), Proteolysis

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

B-Cell LymphomaB-Cell Malignant Neoplasm

Inactive Indication-

Originator Organization

Sichuan Haisco Pharmaceutical Co., Ltd.

Active Organization

Haisco Pharmaceutical Group Co., Ltd.

Sichuan Haisco Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估HSK29116在复发或难治性B细胞恶性肿瘤受试者中不同给药方案的安全性。次要目的：评估HSK29116在复发或难治性B细胞恶性肿瘤受试者中不同给药方案的初步有效性；评估HSK29116在复发或难治性B细胞恶性肿瘤受试者中不同给药方案的体内PK（药代动力学）和PD（药效动力学）特征。

[Translation]

Primary objective: To evaluate the safety of different dosing regimens of HSK29116 in subjects with relapsed or refractory B-cell malignancies. Secondary objective: To evaluate the preliminary efficacy of different dosing regimens of HSK29116 in subjects with relapsed or refractory B-cell malignancies; To evaluate the in vivo PK (pharmacokinetics) and PD (pharmacodynamics) characteristics of different dosing regimens of HSK29116 in subjects with relapsed or refractory B-cell malignancies.

Start Date30 Oct 2023

Sponsor / Collaborator

Sichuan Haisco Pharmaceutical Co., Ltd.

NCT04861779

/ Unknown statusPhase 1

A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of HSK29116 in patients with advanced B-cell malignancies.

Start Date24 Aug 2021

Sponsor / Collaborator

Haisco Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with HSK-29116

Login to view more data

100 Translational Medicine associated with HSK-29116

Login to view more data

100 Patents (Medical) associated with HSK-29116

Login to view more data

100 Deals associated with HSK-29116

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-Cell Lymphoma	Phase 1	United States	Haisco Pharmaceutical Group Co., Ltd.	14 Apr 2022
B-Cell Malignant Neoplasm	Phase 1	China	Sichuan Haisco Pharmaceutical Co., Ltd.	30 Jul 2021